Menadione bisulfite

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Menadione bisulfite
DrugBank Accession Number
DB15944
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 254.26
Monoisotopic: 254.024894596
Chemical Formula
C11H10O5S
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Albutrepenonacog alfaMenadione bisulfite may increase the thrombogenic activities of Albutrepenonacog alfa.
Alpha-1-proteinase inhibitorAlpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione bisulfite.
AlteplaseThe therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Alteplase.
Aminocaproic acidAminocaproic acid may increase the thrombogenic activities of Menadione bisulfite.
Andexanet alfaMenadione bisulfite may increase the thrombogenic activities of Andexanet alfa.
AnistreplaseThe therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Anistreplase.
Anti-inhibitor coagulant complexMenadione bisulfite may increase the thrombogenic activities of Anti-inhibitor coagulant complex.
Antihemophilic factor (recombinant), PEGylatedMenadione bisulfite may increase the thrombogenic activities of Antihemophilic factor (recombinant), PEGylated.
Antihemophilic factor humanMenadione bisulfite may increase the thrombogenic activities of Antihemophilic factor human.
Antihemophilic factor, human recombinantMenadione bisulfite may increase the thrombogenic activities of Antihemophilic factor, human recombinant.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Menadione sodium bisulfite anhydrous97K34V88SA130-37-0XDPFHGWVCTXHDX-UHFFFAOYSA-M
Menadione sodium bisulfite trihydrate6XF3C2HK776147-37-1Not applicable

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
I2BE1ZEN8I
CAS number
130-36-9
InChI Key
WIXFIQKTHUVFDI-UHFFFAOYSA-N
InChI
InChI=1S/C11H10O5S/c1-11(17(14,15)16)6-9(12)7-4-2-3-5-8(7)10(11)13/h2-5H,6H2,1H3,(H,14,15,16)
IUPAC Name
2-methyl-1,4-dioxo-1,2,3,4-tetrahydronaphthalene-2-sulfonic acid
SMILES
CC1(CC(=O)C2=C(C=CC=C2)C1=O)S(O)(=O)=O

References

General References
Not Available
ChemSpider
8220
ChEBI
63930
ChEMBL
CHEMBL1159684

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.86 mg/mLALOGPS
logP-0.47ALOGPS
logP0.87ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)-1.5ChemAxon
pKa (Strongest Basic)-7.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area88.51 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity59.81 m3·mol-1ChemAxon
Polarizability23.27 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on November 25, 2020 21:38 / Updated on July 29, 2021 04:17